Kinesin spindle protein inhibitors in cancer: from high throughput screening to novel therapeutic strategies

  • Future Sci OA. 2022 Feb 21;8(3):FSO778. doi: 10.2144/fsoa-2021-0116.
Rand Shahin  1 Salah Aljamal  2
Affiliations
  • 1. he Hashemite University, Faculty of Pharmaceutical Sciences, Department of Pharmaceutical Chemistry, P.O. Box 330127, Al-Zarqa 13133, Jordan.
  • 2. Faculty of pharmacy, University of Jordan, Amman, 11942, Jordan.
Abstract

Bringing to a halt the cell cycle in Mitosis and interfering with its normal progression is one of the most successful anti-cancer strategies used nowadays. Classically, several kinds of anti-cancer drugs like taxanes and vinca Alkaloids directly inhibit microtubules during cell division. These drugs exhibit serious side effects, most importantly, severe peripheral neuropathies. Alternatively, KSP inhibitors are grasping a lot of research attention as less toxic mitotic inhibitors. In this review, we track the medicinal chemistry developmental stages of KSP inhibitors. Moreover, we address the challenges that are faced during the development of KSP inhibitor therapy for Cancer and future insights for the latest advances in research that are directed to find active KSP inhibitor drugs.

Keywords
Eg5; KIF11; KSP; filanesib; ispinesib; kinesin spindle protein; litronesib; monastrol.
Products